about
PembrolizumabNew treatments for metastatic melanomaEffect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaBurden of illness for metastatic melanoma in Canada, 2011-2013Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialAssessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsEnzalutamide in metastatic prostate cancer before chemotherapy.Renal cell carcinoma bone metastases: clinical advancesA phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancerRetinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanomaEffect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagyMelanoma prevention: are we doing enough? A Canadian perspective.Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.Web-based resources for clinical bioinformatics.Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).Prostate cancer as a model system for genetic diversity in tumors.Carney complex with adrenal cortical carcinoma.Beyond castration-defining future directions in the hormonal treatment of prostate cancer.The changing landscape in metastatic castration-resistant prostate cancer.Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review.Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.A randomized phase II trial of geriatric assessment and management for older cancer patients.Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
P50
Q26796435-DBF35247-42A2-4B70-8D85-EC6F761E7D93Q27007068-851FF23C-DC83-46EA-A48D-FEA9FA8DF278Q27853021-41714650-7967-4685-B682-E7939D7F33D0Q27860650-AA778A8C-BE0C-45E2-8D1E-7C14C3ABA00BQ28354125-1FF3096A-B221-413D-86CE-6BC2C47B33FDQ29620814-CF9D2E12-C551-422D-8390-D53CFF5AE1D3Q30000285-6CB25076-FF77-4AE8-BADF-23D61F9B51FFQ30826387-93123FC8-EFDA-47B6-BD78-F93793DFC52CQ30836526-5F680B4A-F4D6-4397-8FD1-8DD53F78ED3DQ33750205-B9DA1D48-1F48-4D1B-A242-50BAE3F61DFFQ33840135-529CEFA2-1958-4D21-B945-B00C77BB5430Q34324736-F9FAC7CB-8F5E-43DC-8EA7-BD4A431CF82CQ34422206-1E284250-5172-42B0-AE02-1FA048DE999EQ34631216-D17EF978-C35F-49EB-B331-65CF42F15AEDQ34657338-A8E71B84-D147-4F0E-BA50-D04753BF19F3Q34707054-9C936C85-654F-4DFF-9CD5-46FE7798913FQ35678695-26FF5280-A9AA-4032-8BDE-683638E0AB90Q36416274-42246F2C-7266-4A1D-AD17-B3BF2C5C29D9Q36524863-2A9BF6CF-027A-4B29-8F0D-DC71AF2CABDDQ36833801-4978813E-1634-4082-9321-AEA4C8EA2965Q37153137-B185703B-B329-4179-BE8B-A24EE74DC740Q37257453-E9502CC4-FE86-4310-91A1-1B8BA305D1ACQ37350763-E6C53726-4E07-482F-A17E-21EF15B6FA35Q37429108-D9683136-68BA-4973-8A44-70F8FA56EFC2Q37933898-17061973-ABF3-4481-A567-BF6AA411F984Q37960278-C05706CC-33E3-4D67-BA53-E1E1F18745D7Q37962393-00EF06F0-3749-4ED7-8787-6B759B3DA5D6Q38118576-ACBB2C67-1BDE-4190-947F-FB165DEB678AQ38220840-811C0F79-A4B3-436B-BE2F-1FAB23A3E3B2Q38231749-02A8A8F8-EA2C-48FD-9AED-95E9FB228741Q38258700-B13983BE-F494-4754-B04A-984A3920BBDFQ38373372-91EBD8FE-3EE0-4A3D-8067-75327D837971Q38383826-57EA68A2-5F47-48DF-8FC1-3E045FAB4EC4Q38388321-804B8698-B42B-40F2-980F-CB3D61717CB8Q38393470-32F07B12-F9BE-4BAB-A24F-EC54D36CF323Q38405404-11628051-C2C8-44FB-98AD-3B2AAEEF9121Q38535099-A34F4EDF-DB91-4EA7-9C7F-7A147B5D2F09Q38664856-C8CE988D-D063-4CA8-A4E2-77624E2A84FDQ38708875-CDEAA749-2D15-4E61-9C0D-97883AA3A476Q38914959-22D60C46-FAB2-4EBA-AE7F-CB08A26D2B20
P50
description
researcher ORCID ID = 0000-0001-5159-4580
@en
wetenschapper
@nl
name
Anthony M Joshua
@ast
Anthony M Joshua
@en
Anthony M Joshua
@es
Anthony M Joshua
@nl
type
label
Anthony M Joshua
@ast
Anthony M Joshua
@en
Anthony M Joshua
@es
Anthony M Joshua
@nl
prefLabel
Anthony M Joshua
@ast
Anthony M Joshua
@en
Anthony M Joshua
@es
Anthony M Joshua
@nl
P106
P21
P31
P496
0000-0001-5159-4580